ALK and non-small cell lung carcinoma: In the phase 3, open-label, randomized ALINA trial, patients who had undergone lobectomy for non-squamous ALK-positive NSCLC were assigned to either two years of adjuvant alectinib or four cycles of platinum-based chemotherapy [60].